Oak Ridge Investments LLC Has $1.09 Million Stock Position in argenx SE (NASDAQ:ARGX)

Oak Ridge Investments LLC cut its stake in argenx SE (NASDAQ:ARGX - Free Report) by 60.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,769 shares of the company's stock after selling 2,696 shares during the period. Oak Ridge Investments LLC's holdings in argenx were worth $1,088,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ARGX. Cromwell Holdings LLC boosted its position in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after buying an additional 66 shares during the period. GAMMA Investing LLC lifted its stake in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company's stock valued at $94,000 after acquiring an additional 56 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in argenx during the 2nd quarter worth approximately $76,000. Fulton Bank N.A. acquired a new position in argenx during the 4th quarter worth approximately $226,000. Finally, Blue Trust Inc. grew its stake in shares of argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company's stock worth $201,000 after acquiring an additional 298 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on ARGX. Robert W. Baird cut shares of argenx from an "outperform" rating to a "neutral" rating and increased their target price for the stock from $515.00 to $650.00 in a report on Friday, November 1st. William Blair upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a research note on Friday, November 1st. Oppenheimer reaffirmed an "outperform" rating and issued a $675.00 target price (up previously from $646.00) on shares of argenx in a research report on Thursday, November 21st. Scotiabank raised argenx from a "sector perform" rating to a "sector outperform" rating and increased their price target for the company from $439.00 to $715.00 in a research report on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $717.00 price target (up previously from $670.00) on shares of argenx in a research report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, argenx currently has an average rating of "Moderate Buy" and a consensus target price of $658.39.

argenx Trading Down 2.9 %

Shares of NASDAQ:ARGX traded down $19.29 during trading on Friday, reaching $640.52. 483,293 shares of the stock were exchanged, compared to its average volume of 186,140. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21. The stock has a 50-day moving average price of $620.19 and a 200-day moving average price of $557.36. The firm has a market cap of $38.67 billion, a PE ratio of -727.86 and a beta of 0.59.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period in the previous year, the company posted ($1.25) EPS. On average, sell-side analysts expect that argenx SE will post 2.17 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.